ChemoCentryx Inc (ChemoCentryx) is a bio pharmaceutical company that discovers, develops and commercializes orally-administered therapeutics for the treatment of cancer, autoimmune diseases and inflammatory disorders. The company's lead drug candidate include Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; CCX872, an orally administered inhibitor for pancreatic cancer; and CCX140, an orally-administered inhibitor of the chemokine receptor known for patients with diabetic nephropathy, among others. It also carries out preclinical research for evaluating the effect of combination therapy with chemokine receptor and check point inhibitors. ChemoCentryx is headquartered in Mountain View, California, the US.
Headquarters
United States of America
Address
835 Industrial Road, Suite 600, San Carlos, California, 94070
Website
www.chemocentryx.com
Telephone
1 650 2102900
No of Employees
178
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CCXI (NASD)
Revenue (2020)
$32.2M
-50.3%
(2020 vs 2019)
EPS
XXX
Net Income (2020)
XXX
-138%
(2020 vs 2019)
Market Cap*
$3.6B
Net Profit Margin (2020)
XXX
-379.3%
(2020 vs 2019)
* As of and is in US$
Access premium data and analytics for ChemoCentryx Inc
Products and Services
| Products |
|---|
| Pipeline |
| CCX168 : for the treatment of Orphan and Rare Diseases |
| CCX140 : for the treatment of Diabetic Nephropathy |
| XXX |
| XXX |
| XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Contracts/Agreements | In August, the company agreed to be acquired by Amgen Inc for US$3.7 billion. |
| 2022 | Regulatory Approval | In January, the company approved within the European Union in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA). |
| 2017 | Regulatory Approval | In March, the company received the US FDA's Orphan Drug Designation for its avacopan, to treat C3 glomerulopathy (C3G) patients. |
Competitor Comparison
| Key Parameters | ChemoCentryx Inc | Assertio Therapeutics Inc | Enzo Biochem Inc | MediciNova Inc | Galectin Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Carlos | Lake Forest | Farmingdale | La Jolla | Norcross |
| State/Province | California | Illinois | New York | California | Georgia |
| No. of Employees | 178 | - | 451 | 11 | 9 |
| Entity Type | Public | Private | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Thomas J. Schall, Ph.D. | Chairman; Chief Executive Officer; President | Executive Board | 2012 | 61 |
| Rita Jain, M.D. | Chief Medical Officer; Director; Senior Vice President | Executive Board | 2019 | 58 |
| Susan M. Kanaya | Chief Financial Officer; Chief Administrative Officer; Secretary; Executive Vice President | Senior Management | 2021 | 58 |
| Tausif Butt | Chief Operating Officer; Executive Vice President | Senior Management | 2021 | - |
| Catherine L. Kelleher | Senior Vice President - Clinical Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer